Search Results - "Foerster, Frank Gerhard"

Nationwide Survey of German Outpatient Gynecologic Oncology Practices during the Coronavirus Disease 2019 Pandemic: Reactions to the First Wave and Future Perspectives by Vu, Erwin, Schröder, Christina, Dülk, Jonas, Stelmes, Jean-Jacques, Vu, Jennifer, Schilling, Jörg, Förster, Frank Gerhard, Förster, Robert

“…Abstract Introduction: In the spring of 2020, coronavirus disease 2019 posed a substantial challenge for countries and their healthcare systems. In Germany,…”
Get full text

Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment by Schneeweiss, Andreas, Schmidt, Marcus, Foerster, Frank Gerhard, Geberth, Matthias, Tesch, Hans, Klare, Peter, Schumacher, Claudia, Hollburg, Wiebke, Soeling, Ulrike, Aktas, Bahriye, Kutscheidt, Andreas, Kümmel, Sherko

“…Abstract only…”
Get full text

Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial by Marme, Frederik, Gerber, Bernd, Schmidt, Marcus, Moebus, Volker Jochen, Foerster, Frank Gerhard, Grischke, Eva-Maria, Beckmann, Matthias W., Strumberg, Dirk, Solomayer, Erich, Klare, Peter, Windemuth-Kieselbach, Christiane, Schneeweiss, Andreas

“…Abstract only…”
Get full text

Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the first interim analysis of the noninterventional trial BRAWO by Lueftner, Diana, Schuetz, Florian, Grischke, Eva-Maria, Fasching, Peter A., Wimberger, Pauline, Foerster, Frank Gerhard, Decker, Thomas, Uleer, Christoph, Muth, Mathias, Kreuzeder, Julia, Bloch, Wilhelm, Tesch, Hans, Jackisch, Christian

“…Abstract only…”
Get full text

Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study by Schrader, Iris, Foerster, Frank Gerhard, Schneeweiss, Andreas, Geberth, Matthias, Hahn, Lars, Schumacher, Claudia, Hertz-Eichenrode, Martin Michael, Schoenegg, Winfried, Wolfgarten, Matthias Kim, Kutscheidt, Andreas, Schmidt, Marcus, Aktas, Bahriye

“…Abstract only 1077 Background: 1st-line BEV combined with weekly PAC significantly improves progression-free survival (PFS) and response rate (RR) vs PAC alone…”
Get full text

Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy by Hanker, Lars Christian, Hitschold, Thomas, Hesse, Tobias, Grafe, Andrea, Foerster, Frank Gerhard, Schroeder, Jan Klaus, Janssen, Jan, Reichert, Dietmar Arno, Hielscher, Carsten, Greinemann, Jasmin, Borquez, David Julian, Schmidt, Marcus

“…Abstract only 602 Background: Addition of trastuzumab (Roche; T) to chemotherapy (CT) has improved outcomes in patients (pts) with HER2+ breast cancer at all…”
Get full text